REPROCELL and VIROCLINICS-DDL Launch New Collaboration in Clinical Research
17 August 2020
Rotterdam, The Netherlands, VIROCLINICS-DDL is pleased to announce the signing of a new collaboration agreement with REPROCELL. REPROCELL will provide sample processing services to VIROCLINICS-DDL to support several clinical research projects.
VIROCLINICS-DDL is the global leader in clinical trial management services, focused on viral targets such as influenza, COVID-19, RSV, HBV and Polio.
REPROCELL will provide sample processing services in Japan to VIROCLINICS-DDL and will support influenza clinical research projects from September 2020 until April 2021. REPROCELL will join VIROCLINICS-DDL’s extensive global processing laboratory network to assist with several clinical research studies.
“This new collaboration signifies REPROCELL’s global capabilities in human biospecimen processing and handling”, said Dr. David Bunton, CEO REPROCELL EUROPE Ltd. “We are excited to enter the clinical trial business through this partnership with VIROCLINICS-DDL” he continued.
Processing laboratories are vital for supporting virology clinical trials given the perishable nature of the samples. It is essential to work with partners who can guarantee sample integrity. “In REPROCELL we have found a strategic partner with an excellent track record of processing human biospecimens”, said Davide Molho DVM, CEO VIROCLINICS-DDL. “We are excited to team up with REPROCELL and look forward to embracing the many opportunities that lie ahead”.
About Viroclinics-DDL VIROCLINICS-DDL is a leading virology contract research organization, serving the biopharmaceutical community with a broad range of preclinical, clinical diagnostic, assay development and clinical trial logistics services. Operating at a global level, VIROCLINICS-DDL is the preferred virology testing laboratory for several of the top-10 biopharmaceutical companies. VIROCLINICS-DDL’s extensive experience with clinical and preclinical studies for viruses, including its specialty in respiratory viruses, puts the company at the forefront in supporting the development of vaccines, antibodies and antiviral compounds targeting viral infectious diseases. VIROCLINICS-DDL is based in the Netherlands and employs more than 270 well-trained, dedicated scientists and technical experts. More info: www.viroclinics.com / www.ddl.nl About REPROCELL REPROCELL was established in 2003 to accelerate medical research via cutting-edge stem cell and human tissue-based technologies, including the use of novel transfection reagents and RNA-based methods for the generation of induced pluripotent stem cells. REPROCELL has further diversified its portfolio of products and services to include predictive drug discovery services in human fresh tissues, technologies for the manufacture of bioengineered human tissues, industry-leading gene editing technology and one of the largest commercial repositories of ethically sourced human tissue. More info: www.reprocell.com